Publicaciones en las que colabora con JOSÉ LUÑO FERNÁNDEZ (71)

2021

  1. Obesity related risk for chronic kidney disease progression and cardiovascular disease after propensity score matching

    Hipertension y Riesgo Vascular, Vol. 38, Núm. 2, pp. 63-71

  2. Riesgo relacionado con la obesidad para la progresión de insuficiencia renal crónica y enfermedad cardiovascular tras emparejamiento por puntaje de propensión

    Hipertensión y riesgo vascular, Vol. 38, Núm. 2, pp. 63-71

2020

  1. COVID-19: clinical course and outcomes of 36 hemodialysis patients in Spain

    Kidney International

  2. Chronic kidney disease progression in patients with resistant hypertension subject to 2 therapeutic strategies: Intensification with loop diuretics vs aldosterone antagonists

    Nefrologia, Vol. 40, Núm. 1, pp. 66-74

  3. Progresión de la enfermedad renal crónica en pacientes con hipertensión resistente sometidos a 2 estrategias terapéuticas: intensificación con diuréticos de asa vs. antagonistas de la aldosterona

    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, Vol. 40, Núm. 1, pp. 65-73

2019

  1. An old disease, a new diagnosis; A 49 year-old man with nephrotic syndrome

    Journal of Nephropathology, Vol. 8, Núm. 3

  2. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials

    The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 2, pp. 128-139

  3. Mixed cryoglobulinaemia vasculitis after sustained hepatitis C virological response with direct-acting antivirals

    Clinical Kidney Journal, Vol. 12, Núm. 3, pp. 362-364

  4. Obesity and chronic kidney disease progression-the role of a new adipocytokine: C1q/tumour necrosis factor-related protein-1

    Clinical Kidney Journal, Vol. 12, Núm. 3, pp. 420-426

  5. Pentoxifylline, progression of chronic kidney disease (CKD) and cardiovascular mortality: long-term follow-up of a randomized clinical trial

    Journal of Nephrology, Vol. 32, Núm. 4, pp. 581-587

2018

  1. Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study)

    Cardiovascular Drugs and Therapy, Vol. 32, Núm. 3, pp. 255-263

  2. Atypical haemolytic uremic syndrome: when multiple etiologies meet

    International Urology and Nephrology

  3. Hyperuricemia is associated with progression of chronic kidney disease in patients with reduced functioning kidney mass

    Nefrologia, Vol. 38, Núm. 1, pp. 73-78

  4. Impact of anticoagulation and platelet antiaggregation on anaemia and haemorragic events in patients with chronic kidney disease stages 3 and 4

    Medicina Clinica, Vol. 151, Núm. 12, pp. 476-480

  5. Impact of the application of the JNC 8 and KDIGO-2013 guidelines on hypertension and lipid control in a nephrology outpatient clinic

    Nefrologia, Vol. 38, Núm. 4, pp. 373-379

  6. Impacto de la aplicación del 8.o JNC y de las guías KDIGO-2013 en el control de la hipertensión arterial y los lípidos en una consulta de Nefrología

    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, Vol. 38, Núm. 4, pp. 379-385

2017

  1. Cardiovascular risk prediction in chronic kidney disease patients

    Nefrologia, Vol. 37, Núm. 3, pp. 293-300

  2. Lesinurad: What the nephrologist should know

    Clinical Kidney Journal, Vol. 10, Núm. 5, pp. 679-687

  3. Low dose aspirin increases 15-epi-lipoxin A4 levels in diabetic chronic kidney disease patients

    Prostaglandins Leukotrienes and Essential Fatty Acids, Vol. 125, pp. 8-13

2016

  1. Asymptomatic intradialytic supraventricular arrhythmias and adverse outcomes in patients on hemodialysis

    Clinical Journal of the American Society of Nephrology, Vol. 11, Núm. 12, pp. 2210-2217